查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993112

犬用疫苗市場：2026年至2032年全球市場預測（依疫苗類型、科技、動物年齡層、通路和最終用戶分類）

Dog Vaccines Market by Vaccine Type, Technology, Animal Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，犬用疫苗市場價值將達到 24 億美元，到 2026 年將成長至 26 億美元，到 2032 年將達到 41.8 億美元，複合年成長率為 8.26%。

主要市場統計數據
基準年 2025 24億美元
預計年份：2026年 26億美元
預測年份：2032年 41.8億美元
複合年成長率 (%) 8.26%

簡要概述現代犬用疫苗領域，將科學創新與商業性現實和營運影響聯繫起來。

科學進步、寵物飼主不斷變化的期望以及監管趨勢正在推動犬類健康管理領域的持續發展。本執行摘要在於犬用疫苗領域，概述了影響相關人員決策的關鍵促進因素、新興方法和商業性趨勢。其目的是幫助企業主管、臨床醫生和產品負責人了解影響疫苗研發、分銷和應用的結構性動態，並為營運管理和投資優先排序提供實用見解。

技術進步、獸醫保健模式的變革以及更嚴格的監管，都在促成犬用疫苗。

近年來，多項變革性變化重塑了犬用疫苗的研發、評估和交付，為價值鏈上的所有相關人員帶來了機會和挑戰。分子平台技術的進步開闢了新的治療途徑，而低溫運輸物流和數位醫療領域的同步發展則改變了分銷模式，並為寵物飼主和獸醫專業人員的互動創造了新的途徑。這些變化也反映了人們期望的更廣泛轉變。寵物飼主越來越傾向於將伴侶動物的健康觀點“人類級別的護理”，從而推動了對更高安全性和更透明的療效數據的需求。

評估 2025 年美國關稅措施對供應鏈韌性、採購決策和下游採購經濟的策略影響。

美國貿易政策趨勢和關稅調整為採購計劃、跨境夥伴關係以及關鍵投入品的供應帶來了新的變數。關稅變化不僅影響成品疫苗的運輸，也影響上游原料、試劑和生產所需專用設備的流動。由於關稅會改變接收成本並促使企業將某些生產活動在獎勵，各組織正在重新審視籌資策略，並評估建立區域生產基地的可行性，以降低貿易波動帶來的風險。

可操作的細分訊息，將疫苗類型、配銷通路趨勢、最終用戶偏好、技術平台和動物年齡層進行匹配，以指導優先戰略選擇。

精準的市場區隔對於最佳化疫苗類型、分銷管道、終端用戶需求、技術平台和動物年齡層的產品開發和市場進入策略至關重要。就疫苗類型而言，去活化疫苗、減毒活病毒疫苗和重組疫苗在研發和臨床應用方面有顯著差異，每種疫苗都有獨特的安全性和儲存特性，這些特性會影響臨床應用和傳播策略。在分銷方面，分銷管道涵蓋醫療機構和零售管道，其中獸醫院、線上零售商、藥局和獸醫診所等都以其獨特的方式影響臨床趨勢、庫存模式和客戶體驗。

從綜合考慮美洲、歐洲、中東、非洲和亞太地區的監管多樣性、分銷管道能力和文化態度出發，建構全面的區域觀點。

區域趨勢在塑造犬用疫苗的監管時間表、分銷基礎設施和競爭格局方面發揮著至關重要的作用，這體現在各個主要區域獨特的商業環境中。在美洲，對伴侶動物醫療保健的高度重視，加上成熟的獸醫網路和私營部門對新平台的大力投資，使得新配方在獲得監管核准和報銷機制後能夠迅速得到推廣。而歐洲、中東和非洲則呈現更為複雜的生態系統，監管協調程度不一，獸醫診所密度和購買力也有差異。考慮到所有這些因素，必須制定符合當地合規性和流通結構的市場准入和市場拓展策略。

對犬用疫苗領域進行策略競爭格局分析，闡述現有公司的優勢、生物技術創新和製造夥伴關係關係如何融合，從而創造差異化的競爭優勢。

犬用疫苗領域的競爭動態受到多種因素的影響，包括成熟的獸用生物製品公司、創新生物技術參與企業以及支持專業平台規模化生產的契約製造（CMO）。成熟公司在分銷網路、獸醫信任度和監管合規經驗方面保持優勢，而新參與企業通常具備平台靈活性和差異化策略，能夠快速適應新的靶點，例如mRNA和基於載體的構建體。夥伴關係與授權協議是將商業性覆蓋範圍與技術新穎性相結合的常用機制，而與合約開發和生產組織（CDMO）建立策略聯盟對於那些希望在不大幅增加固定資產資本投入的情況下加快產品上市速度的公司至關重要。

為確保永續的競爭優勢，為高階主管提供可操作的、優先考慮的策略建議，以協調創新、供應鏈韌性、相關人員參與和分銷執行。

動物用藥品領域的領導者應務實地將創新投資、供應鏈強化和相關人員參與相結合，以管控風險並抓住機會。優先考慮能夠滿足臨床未滿足需求且具備可擴展生產能力的平台技術。這意味著評估DNA、mRNA和載體方法時，不僅要考慮其免疫學潛力，還要考慮其可生產性、低溫運輸影響和監管核准管道。同時，制定靈活的籌資策略，確保關鍵試劑的多元化來源，並探索區域生產方案，以降低關稅和運輸中斷帶來的風險。

採用嚴謹的混合方法研究方法，結合關鍵相關人員的訪談、二手技術文獻和情境分析，以檢驗策略見解。

本研究採用混合方法，整合質性和量性訊息，強調三角驗證和具體檢驗。主要資訊來源包括對獸醫、實驗室技術人員、採購負責人和行業高管的結構化訪談，以及針對相關人員的研討會，旨在識別該領域的營運限制和應用促進因素。次要資訊來源包括監管指導文件、同行評審文獻、臨床實驗室報告和專利揭露，目的是確保技術準確性，並將技術趨勢置於科學規範的框架內。

整合策略挑戰和實際考量因素，指導各組織在市場上穩健、以證據為基礎部署犬用疫苗。

總之，犬用疫苗領域處於科學創新、不斷演變的分銷模式以及複雜的監管和貿易環境的交匯點。能夠成功駕馭這一領域的相關人員，需要具備以下能力：將平台技術進步轉化為具有臨床意義的產品；調整分銷和宣傳活動以滿足終端用戶的期望；以及設計能夠抵禦政策和物流干擾的供應鏈。戰略挑戰在於如何將技術雄心與實際可行性結合，以確保新技術能夠安全可靠地惠及動物及其飼主，並建立長期的信任。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：犬用疫苗市場：依疫苗類型分類

  • 去活化疫苗
  • 減毒疫苗
  • 重組疫苗

第9章：犬用疫苗市場：依技術分類

  • DNA
  • mRNA
    • 非複製型
    • 自放大
  • 向量

第10章：犬用疫苗市場：依動物年齡層別分類

  • 成犬
  • 小狗
  • 老年犬

第11章：犬用疫苗市場：依通路分類

  • 動物醫院
  • 線上零售
  • 藥局
  • 動物診所

第12章：犬用疫苗市場：依最終用戶分類

  • 寵物飼主
  • 研究機構
  • 動物醫院

第13章：犬用疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：犬用疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：犬用疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國犬用疫苗市場

第17章：中國犬用疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anicon Labor GmbH by SNA group
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Elanco LLC
  • Endovac Animal Health, LLC
  • Heska Corporation
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Merck KGaA
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • Sanofi SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
Product Code: MRR-1A1A064C028B

The Dog Vaccines Market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.60 billion in 2026, with a CAGR of 8.26%, reaching USD 4.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.40 billion
Estimated Year [2026] USD 2.60 billion
Forecast Year [2032] USD 4.18 billion
CAGR (%) 8.26%

A concise orientation to the contemporary canine vaccine environment that maps scientific innovation to commercial realities and operational implications

The landscape of canine health management is undergoing sustained evolution as scientific advances, shifting pet owner expectations, and regulatory developments converge. This executive summary introduces a focused exploration of the dog vaccines domain, outlining critical drivers, emergent modalities, and the commercial contours that influence stakeholder decision-making. The objective is to orient executives, clinicians, and product strategists to the structural dynamics shaping vaccine development, distribution, and adoption while highlighting the practical implications for operations and investment prioritization.

Across veterinary practice and companion animal care, vaccination remains a cornerstone of preventive medicine. Nonetheless, recent years have seen a widening array of vaccine technologies, diversified delivery pathways, and more sophisticated demand signals from pet owners who increasingly value safety, convenience, and evidence of efficacy. This introduction frames subsequent sections by underscoring the interplay between scientific innovation and market-facing execution, setting expectations for how strategic choices will affect organizational competitiveness and animal welfare outcomes.

Moving forward, the assessment emphasizes translation of scientific capability into accessible products, the influence of channel economics on uptake, and the role of regulatory clarity in enabling novel modalities. In doing so, it prepares readers to interpret segmentation-level insights, regional variances, and the implications of trade policy on planning horizons and procurement strategies.

How converging technological advances, shifting veterinary care models, and regulatory tightening are driving a structural transformation across canine vaccine development and delivery

Recent years have seen several transformative shifts that are reshaping how vaccines for dogs are developed, vetted, and delivered, creating both opportunities and constraints for stakeholders across the value chain. Advances in molecular platforms have opened new therapeutic pathways, while parallel progress in cold-chain logistics and digital health has altered distribution models and created room for novel engagement with pet owners and veterinary professionals. These shifts also reflect broader changes in expectations: pet owners increasingly view companion animal health through a lens of human-grade care, driving demand for higher safety profiles and more transparent efficacy data.

At the same time, regulatory agencies have become more proactive in articulating requirements for newer modalities, leading to clearer pathways for DNA, mRNA, and vector-based candidates but also imposing stringent demonstration of long-term safety. The proliferation of online retail and telehealth-enabled veterinary services has disrupted traditional distribution norms and forced incumbents to adapt service models and client communications. Furthermore, integration of genomic surveillance and pathogen mapping into routine practice is enabling more targeted vaccine design, shortening the loop between outbreak detection and product iteration.

Consequently, innovators and established manufacturers must balance accelerated R&D trajectories with rigorous evidence generation and supply chain resilience. As a result, strategic imperatives now include investment in platform interoperability, enhanced stakeholder education, and adaptive manufacturing capacity that can respond to both routine immunization schedules and emerging pathogen threats.

Assessing the strategic consequences of United States tariff measures in 2025 on supply chain resilience, sourcing decisions, and downstream procurement economics

Trade policy developments and tariff adjustments enacted by the United States have introduced new variables into planning for procurement, cross-border partnerships, and the supply of critical inputs. Tariff changes affect not only finished vaccine shipments but also the upstream flow of raw materials, reagents, and specialized equipment that are essential to production. As tariffs alter landed costs and create incentives to localize specific manufacturing activities, organizations are reassessing sourcing strategies and evaluating the feasibility of regional production hubs to mitigate exposure to trade volatility.

These shifts have also prompted companies to reexamine contractual frameworks with suppliers and distributors, placing greater emphasis on flexibility clauses and dual-sourcing arrangements. In parallel, licensors and contract manufacturers are exploring alternative commercial models that can cushion the impact of tariff-induced cost fluctuations, including long-term supply agreements and onshore capacity investments. For stakeholders engaged in clinical development, changes in import duties affecting laboratory reagents and animal health diagnostics are being monitored closely, since procurement timelines may be lengthened when sourcing corridors become less predictable.

Ultimately, the cumulative impact of tariff measures in 2025 is encouraging a strategic pivot toward resilient supply chain design, stronger supplier relationships, and greater transparency into total landed costs. Executives should consider tariff exposure as one component of a broader risk management framework that includes regulatory, operational, and reputational factors.

Actionable segmentation intelligence that aligns vaccine type, channel dynamics, end-user preferences, technological platforms, and animal age cohorts to inform prioritized strategic choices

A nuanced understanding of segmentation is essential for tailoring product development and go-to-market strategies across vaccine modality, distribution pathways, end-user needs, technological platforms, and animal age cohorts. When considering vaccine type, there is a clear differentiation in development and clinical profiling between inactivated preparations, live attenuated formulations, and recombinant constructs, each presenting unique safety and storage characteristics that influence clinical adoption and communication strategies. Transitioning to distribution considerations, channels span institutional settings and consumer-facing outlets, with Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each shaping point-of-care dynamics, stocking patterns, and customer experience in distinct ways.

End-user segmentation reveals divergent decision criteria: Pet Owners prioritize convenience, perceived safety, and value communication; Research Institutes focus on assay compatibility and reproducibility for experimental work; Veterinary Hospitals require proven efficacy, ease of administration, and reliable supply. Technological segmentation is particularly consequential as DNA, mRNA, and Vector platforms demonstrate different timelines for regulatory validation, manufacturing scaling, and cold-chain dependencies; within mRNA there is further technical distinction between Non-Replicating and Self-Amplifying formats, which carries implications for dosing, immunogenicity, and production throughput. Age-based segmentation underscores clinical differentiation across Adult, Puppy, and Senior cohorts, given that immune competency, dosing schedules, and comorbidity profiles vary with age and thereby impact safety monitoring and communication strategies.

Integrated segmentation analysis indicates that winning strategies will align product profiles with channel economics and end-user expectations while leveraging platform advantages selectively for age cohorts that realize the greatest clinical benefit. Accordingly, cross-functional planning teams should map segmentation intersections to prioritize clinical programs, distribution investments, and educational outreach that resonate with each stakeholder cluster.

Comprehensive regional vantage points that reconcile regulatory diversity, channel capacity, and cultural attitudes across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a fundamental role in shaping regulatory timelines, distribution infrastructure, and the competitive landscape for canine vaccines, with distinct operating contexts across major geographies. In the Americas, a strong emphasis on companion animal health services is paired with well-established veterinary networks and robust private-sector investment in novel platforms, which fosters rapid uptake of new formulations when regulatory clearance and reimbursement-like mechanisms align. Conversely, Europe, Middle East & Africa presents a more heterogeneous ecosystem characterized by variable regulatory harmonization, differences in veterinary practice density, and diverse purchasing power, all of which necessitate tailored launch and access strategies that account for localized compliance and channel structures.

Asia-Pacific exhibits a mix of high-volume markets with rapidly modernizing veterinary infrastructure and emerging regions where access constraints and differing clinical priorities shape demand. Across all regions, cold-chain logistics, import regulations, and local manufacturing capacity influence placement decisions and partnership models. Moreover, cultural attitudes toward pet ownership, preventive care awareness, and the role of veterinarians in guiding vaccination choices introduce behavioral nuances that companies must address through locally adapted education and outreach programs.

Taken together, regional planning should emphasize regulatory due diligence, partnership selection that leverages local channel strengths, and investment in distribution capabilities that reflect the operational realities of each geography. This regional sensitivity will enable more effective product rollouts and greater alignment with clinician and pet owner expectations.

Strategic competitive landscape analysis showing how incumbent strengths, biotech innovation, and manufacturing partnerships converge to create differentiated advantage in the canine vaccine sector

Competitive dynamics in the dog vaccine sector are being influenced by a mix of established veterinary biologics firms, innovative biotechnology entrants, and contract manufacturers that support specialized platform scale-up. Incumbents retain advantages in distribution networks, practitioner trust, and regulatory experience, while newer entrants often bring platform agility and differentiated approaches such as mRNA or vector-based constructs that can be adapted rapidly to emerging targets. Partnerships and licensing deals are common mechanisms to combine commercial reach with technical novelty, and strategic alliances with contract development and manufacturing organizations are critical for firms seeking to accelerate time-to-market without overextending capital investment in fixed assets.

In addition, increasing emphasis on data-driven safety monitoring and post-marketing evidence collection is favoring competitors that can integrate digital tools and real-world data capture into their product propositions. Companies that invest in robust pharmacovigilance frameworks and clinician education programs are more likely to build long-term trust with veterinary professionals and pet owners. Meanwhile, supply chain reliability and the ability to manage cold-chain-sensitive products at scale remain differentiators that affect commercial sustainability. Consequently, market leaders will be those that combine technological innovation with operational excellence and a disciplined approach to regulatory engagement and stakeholder communication.

Practical and prioritized strategic recommendations for executives to align innovation, supply chain resilience, stakeholder engagement, and distribution execution for sustained advantage

Leaders in the animal health arena should pursue a pragmatic blend of innovation investment, supply chain fortification, and stakeholder engagement to capture opportunity while managing risk. First, prioritize platform technologies that align with clinical unmet needs and can be supported by scalable manufacturing; this means evaluating DNA, mRNA, and vector approaches not only for their immunological potential but for manufacturability, cold-chain implications, and regulatory pathways. Concurrently, develop flexible sourcing strategies that include dual suppliers for critical reagents and consider regional production options to reduce exposure to tariff and shipping disruptions.

Second, invest in clinician and owner education to foster confidence in newer modalities and to clarify administration schedules across life stages from puppy through senior animals. Third, enhance pharmacovigilance and real-world evidence programs to accelerate acceptance and to inform iterative product improvement. Fourth, design distribution strategies that reflect channel-specific behaviors, ensuring that Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each receive tailored product presentation, training, and logistical support. Finally, cultivate strategic partnerships with research institutions and contract manufacturers to balance in-house capability with external expertise and capacity, enabling rapid responses to pathogen emergence while maintaining operational discipline.

A rigorous mixed-methods research approach that integrates primary stakeholder interviews, secondary technical literature, and scenario analysis to validate strategic insights

This research synthesizes qualitative and quantitative inputs through a mixed-methods approach that emphasizes triangulation and subject-matter validation. Primary inputs include structured interviews with veterinary clinicians, laboratory scientists, procurement professionals, and industry executives, complemented by targeted stakeholder workshops that surfaced on-the-ground operational constraints and adoption drivers. Secondary sources encompass regulatory guidance documents, peer-reviewed literature, clinical trial reports, and patent disclosures to ensure technical accuracy and to situate technological trends within the scientific canon.

Analytical methods included cross-segmentation mapping to identify high-impact intersections among vaccine type, distribution channels, end-user priorities, technology platform, and animal age group. Scenario analysis was applied to evaluate supply chain and trade-policy sensitivities, while expert review panels validated assumptions and interpretation of complex technical issues. Throughout the process, care was taken to corroborate claims with multiple evidence streams and to document uncertainty explicitly, enabling readers to distinguish between well-supported insight and areas requiring further empirical work. This methodological rigor underpins the recommendations and ensures that strategic choices are grounded in a defensible evidentiary base.

A synthesis of strategic imperatives and practical considerations that guide organizations toward resilient, evidence-driven deployment of canine vaccines across markets

In closing, the dog vaccines domain sits at the intersection of scientific innovation, evolving distribution models, and complex regulatory and trade environments. Stakeholders who successfully navigate this space will be those that translate platform advances into clinically meaningful products, adapt distribution and education to meet end-user expectations, and design supply chains that withstand policy and logistical disruption. The strategic imperative is to couple technological ambition with operational pragmatism so that new modalities can reach animals and owners safely, reliably, and in a way that supports long-term trust.

Looking ahead, the organizations that win will be those that build adaptive capability across R&D, manufacturing, and commercial operations, while maintaining a relentless focus on evidence generation and stakeholder communication. By aligning segmentation-specific product design with regional realities and robust risk management, leaders can achieve durable impact in improving canine health outcomes and in creating sustainable commercial pathways for next-generation vaccines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dog Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated
  • 8.3. Recombinant

9. Dog Vaccines Market, by Technology

  • 9.1. DNA
  • 9.2. mRNA
    • 9.2.1. Non-Replicating
    • 9.2.2. Self-Amplifying
  • 9.3. Vector

10. Dog Vaccines Market, by Animal Age Group

  • 10.1. Adult
  • 10.2. Puppy
  • 10.3. Senior

11. Dog Vaccines Market, by Distribution Channel

  • 11.1. Animal Hospitals
  • 11.2. Online Retail
  • 11.3. Pharmacies
  • 11.4. Veterinary Clinics

12. Dog Vaccines Market, by End User

  • 12.1. Pet Owners
  • 12.2. Research Institutes
  • 12.3. Veterinary Hospitals

13. Dog Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dog Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dog Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dog Vaccines Market

17. China Dog Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anicon Labor GmbH by SNA group
  • 18.6. Biogenesis Bago S.A.
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Brilliant Bio Pharma Private limited
  • 18.9. Ceva Sante Animale
  • 18.10. China Animal Husbandry Industry Co., Ltd.
  • 18.11. Elanco LLC
  • 18.12. Endovac Animal Health, LLC
  • 18.13. Heska Corporation
  • 18.14. Hester Biosciences Limited
  • 18.15. HIPRA, S.A.
  • 18.16. Indian Immunologicals Limited
  • 18.17. Merck KGaA
  • 18.18. Neogen Corporation
  • 18.19. Phibro Animal Health Corporation
  • 18.20. Sanofi S.A.
  • 18.21. Torigen Pharmaceuticals Inc.
  • 18.22. Vaxxinova GmbH
  • 18.23. VEROVACCiNES GmbH
  • 18.24. Vetoquinol SA
  • 18.25. Virbac, Inc.
  • 18.26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DOG VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DOG VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 131. GCC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GCC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GCC DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 152. G7 DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. G7 DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. G7 DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 159. NATO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. NATO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. NATO DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)